[SCHEDULE 13G/A] Bright Minds Biosciences Inc. SEC Filing

Rhea-AI Filing Summary

Bright Minds Biosciences' Schedule 13G/A shows Sio Capital Management, LLC beneficially owns 512,338 common shares, representing 7.27% of the outstanding class based on 7,043,989 shares disclosed by the issuer. Sio reports shared voting and shared dispositive power and no sole voting or dispositive power. Sio is a Delaware registered investment adviser to affiliated funds that directly hold the reported shares. A footnote states Sio GP, LLC and Michael Castor may be deemed to have influence, though that beneficial ownership is expressly disclaimed. The filer certifies the holdings are held in the ordinary course of business and not to change control.

Positive

• Material institutional stake: Sio beneficially owns 512,338 shares, equal to 7.27% of the class.
• Passive/ordinary-course holding: Filing under Schedule 13G/A and certification state the position is held in the ordinary course and not to change control.

Negative

• Ambiguity about ultimate influence: Footnotes state Sio GP, LLC and Michael Castor may be deemed to have influence over the shares, although that potential beneficial ownership is expressly disclaimed.

Insights

Financial Analyst

TL;DR: Passive institutional stake of 7.27% signals notable investor interest but is reported as non-control and held via affiliated funds.

The filing discloses a material position of 512,338 shares representing 7.27% of Bright Minds' common stock. Because this Schedule 13G/A reports shared voting and shared dispositive power and the filer certifies the holding is in the ordinary course, this reads as a passive institutional ownership disclosure rather than an attempt to influence corporate control. The stake size is large enough to matter for liquidity and shareholder composition, but the explicit non-control posture reduces near-term governance impact.

Corporate Governance Expert

TL;DR: Disclosure is material (>5%) but governance impact is limited by the 13G filing and explicit non-control certification.

The statement confirms Sio Capital Management acts as investment adviser to affiliated funds that directly own the shares and reports no sole voting or dispositive power. A footnote notes that Sio GP, LLC and Michael Castor may be deemed to exert influence, though that potential beneficial ownership is expressly disclaimed. From a governance perspective, the filing signals meaningful ownership concentration without a declared intent to pursue control or activist actions.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Bright Minds Biosciences Inc.

(Name of Issuer)

Common Shares

(Title of Class of Securities)

10919W405

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 10919W405

1

Names of Reporting Persons

Sio Capital Management, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 512,338.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 512,338.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

512,338.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.27 %

12

Type of Reporting Person (See Instructions)

IA

Comment for Type of Reporting Person: 1 As of June 30, 2025, Sio Capital Management, LLC beneficially owned 512,338 shares of Common Stock with shared voting power and shared dispositive power. 2 Based upon 7,043,989 Common Shares outstanding as of January 31, 2025, as disclosed by the Issuer's Prospectus on February 14, 2025.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Bright Minds Biosciences Inc.
(b)	Address of issuer's principal executive offices: 19 Vestry Street, New York, NY, 10013
Item 2.
(a)	Name of person filing: This Statement is filed on behalf of Sio Capital Management, LLC (the "Reporting Person" or "Sio") Sio is a registered investment adviser to certain affiliated funds that directly hold the shares of Common Stock to which this statement relates for the benefit of their respective investors, and in such capacity Sio has voting and dispositive power over such shares.
(b)	Address or principal business office or, if none, residence: 600 Third Avenue, 2nd Floor New York, New York 10016
(c)	Citizenship: Sio is a Delaware limited liability company.
(d)	Title of class of securities: Common Shares
(e)	CUSIP No.: 10919W405
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 512,338
(b)	Percent of class: 7.27%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 512,338 - Refer to footnote 3 3 Sio and Sio GP, LLC (the "GP") act as investment advisor and general partner, respectively, to various clients that are the record owners of the Common Stock reported on this Schedule 13G. Because Sio's investment discretion with respect to such clients is subject to oversight by the GP, the GP may be deemed to be the beneficial owner of the Common Stock of the Issuer owned by such clients. In addition, both Sio and the GP are controlled by Michael Castor. As such, he may be deemed to control the voting and dispositive decisions with respect to, and therefore be the beneficial owner of, the shares of Common Stock reported on this Schedule 13G. Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission by the GP or Michael Castor that such person is the beneficial owner of any of the equity securities referred to herein for purposes of Section 13(d) of the Exchange Act, or for any other purpose, and such beneficial ownership is expressly disclaimed.
	(iii) Sole power to dispose or to direct the disposition of: 0
	(iv) Shared power to dispose or to direct the disposition of: 512,338 - Refer to footnote 3 3 Sio and Sio GP, LLC (the "GP") act as investment advisor and general partner, respectively, to various clients that are the record owners of the Common Stock reported on this Schedule 13G. Because Sio's investment discretion with respect to such clients is subject to oversight by the GP, the GP may be deemed to be the beneficial owner of the Common Stock of the Issuer owned by such clients. In addition, both Sio and the GP are controlled by Michael Castor. As such, he may be deemed to control the voting and dispositive decisions with respect to, and therefore be the beneficial owner of, the shares of Common Stock reported on this Schedule 13G. Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission by the GP or Michael Castor that such person is the beneficial owner of any of the equity securities referred to herein for purposes of Section 13(d) of the Exchange Act, or for any other purpose, and such beneficial ownership is expressly disclaimed.
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Sio Capital Management, LLC

Signature:	/s/ Jin W. Lee
Name/Title:	Chief Compliance Officer
Date:	08/13/2025

FAQ

Who filed the Schedule 13G/A for Bright Minds Biosciences (DRUG)?

The filing was made by Sio Capital Management, LLC, a Delaware registered investment adviser.

How many Bright Minds shares does Sio Capital report owning?

Sio Capital beneficially owns 512,338 common shares of Bright Minds Biosciences.

What percentage of Bright Minds (DRUG) does Sio Capital's position represent?

The reported position represents 7.27% of the outstanding common shares based on the issuer's disclosed share count of 7,043,989.

Does Sio Capital have sole voting or dispositive power over the shares?

No. The filing reports 0 shares with sole voting or dispositive power and 512,338 shares with shared voting and shared dispositive power.

Is the stake intended to influence control of Bright Minds (DRUG)?

The filer certifies the holdings are held in the ordinary course of business and not for the purpose of changing or influencing control.